WILLIAM BYERS: Open Payments
NPI 1053736116 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,115 in 98 payments from 16 companies in 2025. Trend: 2023 $2,363 · 2024 $2,611 · 2025 $2,115
Food & beverage: $2,016Education: $100
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 15 | $272 |
| Teva Pharmaceuticals USA, Inc. | 8 | $254 |
| Vanda Pharmaceuticals Inc. | 11 | $241 |
| ABBVIE INC. | 13 | $239 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $191 |
| Lundbeck LLC | 6 | $190 |
| E.R. Squibb & Sons, L.L.C. | 7 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $126 |
| Neurocrine BioSciences, Inc. | 5 | $112 |
| Alkermes, Inc. | 3 | $79 |
Products named: REXULTI, FANAPT, VRAYLAR, Auvelity, CAPLYTA, AUSTEDO XR, COBENFY, TRINTELLIX.
Industry payments across FL — which companies pay providers there.
